预约演示
更新于：2025-09-02
Atrasentan Hydrochloride
盐酸阿曲生坦
更新于：2025-09-02
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2025-04-02), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)、附条件批准 (中国)、孤儿药 (日本)、特殊审批 (美国)、加速批准 (美国) |
登录后查看时间轴
结构/序列
分子式C29H38N2O6 |
InChIKeyMOTJMGVDPWRKOC-QPVYNBJUSA-N |
CAS号173937-91-2 |
关联
25
项与 盐酸阿曲生坦 相关的临床试验NCT06952426
A Mobile App-Based, Prospective, Observational Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
NCT05834738
A Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy on Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i)
JPRN-jRCT2071210028
A Phase 3, Randomized, Double-blind, Placebocontrolled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function - The ALIGN Study
100 项与 盐酸阿曲生坦 相关的临床结果
登录后查看更多信息
100 项与 盐酸阿曲生坦 相关的转化医学
登录后查看更多信息
100 项与 盐酸阿曲生坦 相关的专利（医药）
登录后查看更多信息
494
项与 盐酸阿曲生坦 相关的文献（医药）2025-04-01COMPUTATIONAL BIOLOGY AND CHEMISTRY
Pharmacoinformatics-based prediction of Checkpoint kinase-1 inhibitors from Momordica charantia Linn. for cancer
Article
作者: Ala, Chandu ; Kunjiappan, Selvaraj ; Murugesan, Sankaranarayanan ; Pandian, Sureshbabu Ram Kumar ; Haripriya, Subramanian ; Vijayalakshmi, Muniyandi ; Pavadai, Parasuraman
Checkpoint kinase 1 (Chk-1), a serine/threonine kinase family protein, is an emerging target in cancer research owing to its crucial role in cell cycle arrest. Therefore, we aimed to predict potential Chk-1 inhibitors from Momordica charantia Linn., using high-throughput molecular docking. We used a graph theoretical network approach to determine the target protein, Chk-1. Among 86 compounds identified from M. charantia L., five molecules such as α-spinasterol (-9.7 kcal × mol-1), stigmasterol (-9.6 kcal × mol-1), stigmasta-7,22,25-trienol (-9.5 kcal × mol-1), campesterol (-9.5 kcal × mol-1), and stigmasta-7,25-dien-3beta-ol (-9.5 kcal × mol-1) and standard drug CCT245737 (-8.3 kcal × mol-1) displayed highest binding affinity with Chk-1. Besides, pharmacokinetic studies have demonstrated the non-toxic and drug-like properties of these compounds. Furthermore, molecular dynamics (MD) simulation studies confirmed the strong intermolecular interactions and stability of the compounds with Chk-1. The estimation of binding free-energy derived from molecular docking was fully recognized by the Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) produced from the MD simulation paths. Altogether, these five compounds may serve as effective inhibitors of Chk-1, thereby could be used to develop new medications for cancer treatment.
2025-04-01Kidney International Reports
Corrigendum to “Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy” [Volume 10, Issue 1, January 2025, Pages 217-226]
作者: Kohan, Donald E ; Levin, Adeera ; Heerspink, Hiddo J L ; Renfurm, Ronny ; Noronha, Irene ; Jardine, Meg ; Trimarchi, Hernan ; Hou, Fan Fan ; Gray, Todd ; Liew, Adrian ; Barratt, Jonathan ; Camargo, Marianne ; Lafayette, Richard A ; Zhang, Hong
[This corrects the article DOI: 10.1016/j.ekir.2024.10.004.].
2025-03-01Nature Reviews Nephrology
Endothelin receptor antagonists in chronic kidney disease
Review
作者: Liew, Adrian ; Kohan, Donald E ; Dhaun, Neeraj ; Smeijer, J David ; Noronha, Irene L ; Heerspink, Hiddo J L
Endothelin-1 is a potent vasoconstrictor that has diverse physiological functions in the kidney, including in the regulation of blood flow and glomerular filtration, electrolyte homeostasis and endothelial function. Overexpression of endothelin-1 contributes to the pathophysiology of both diabetic and non-diabetic chronic kidney disease (CKD). Selective endothelin receptor antagonists (ERAs) that target the endothelin A (ETA) receptor have demonstrated benefits in animal models of kidney disease and in clinical trials. In patients with type 2 diabetes and CKD, the selective ETA ERA, atrasentan, reduced albuminuria and kidney function decline. Concerns about the increased risks of fluid retention and heart failure with ERA use have led to the design of further trials to optimize dosing and patient selection. More recent studies have shown that the dual ETA receptor and angiotensin receptor blocker, sparsentan, preserved kidney function with minimal fluid retention in patients with IgA nephropathy. Moreover, combined administration of a low dose of the ETA-selective ERA, zibotentan, with the sodium-glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, enhanced albuminuria reduction and mitigated fluid retention in patients with CKD. Notably, sparsentan and aprocitentan have received FDA approval for the treatment of IgA nephropathy and treatment-resistant hypertension, respectively. This Review describes our current understanding of the use of ERAs in patients with CKD to guide their optimal safe and effective use in clinical practice.
308
项与 盐酸阿曲生坦 相关的新闻（医药）2025-08-31
·信狐药迅
上市批准疫苗高管变更
2025-08-31
·氨基观察
抗体药物偶联物信使RNA核酸药物基因疗法
2025-08-27
临床3期细胞疗法引进/卖出上市批准临床结果
100 项与 盐酸阿曲生坦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 免疫球蛋白a肾病 | 美国 | 2025-04-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 2型糖尿病肾脏病 | 临床3期 | 美国 | 2013-06-12 | |
| 2型糖尿病肾脏病 | 临床3期 | 日本 | 2013-06-12 | |
| 2型糖尿病肾脏病 | 临床3期 | 阿根廷 | 2013-06-12 | |
| 2型糖尿病肾脏病 | 临床3期 | 澳大利亚 | 2013-06-12 | |
| 2型糖尿病肾脏病 | 临床3期 | 比利时 | 2013-06-12 | |
| 2型糖尿病肾脏病 | 临床3期 | 巴西 | 2013-06-12 | |
| 2型糖尿病肾脏病 | 临床3期 | 加拿大 | 2013-06-12 | |
| 2型糖尿病肾脏病 | 临床3期 | 智利 | 2013-06-12 | |
| 2型糖尿病肾脏病 | 临床3期 | 捷克 | 2013-06-12 | |
| 2型糖尿病肾脏病 | 临床3期 | 丹麦 | 2013-06-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 3,668 | 顧築製築糧製膚積繭繭(窪願積鏇糧鑰壓繭積繭) = Atrasentan showed greater kidney protection in female than in male participants but also induced more heart failure events in the female participants 憲積築製遞齋積糧壓鹽 (觸製憲選齋鹽簾選廠獵 ) | 积极 | 2024-12-11 | |||
临床3期 | 270 | 糧襯襯構餘襯夢襯觸鹹(鏇鹽窪膚衊襯艱鹽鹹製) = 鹹積築遞壓衊艱蓋簾夢 憲廠築顧鹽積範簾選鹽 (淵糧積艱鹽願鬱膚鑰網, -44 ~ -32) | 积极 | 2024-10-25 | |||
Placebo | 糧襯襯構餘襯夢襯觸鹹(鏇鹽窪膚衊襯艱鹽鹹製) = 築淵鏇製淵齋遞構廠觸 憲廠築顧鹽積範簾選鹽 (淵糧積艱鹽願鬱膚鑰網, -12 ~ 7) | ||||||
临床3期 | 1,834 | 鹽鏇顧願膚鏇築構襯齋(廠艱壓壓顧廠選餘糧衊) = 簾鏇獵壓構構鏇壓築齋 鹹廠憲膚築糧鬱艱蓋築 (夢積製鏇齋淵餘憲鑰艱, 0.72 ~ 0.93) | 积极 | 2023-12-01 | |||
Placebo | 鹽鏇顧願膚鏇築構襯齋(廠艱壓壓顧廠選餘糧衊) = 壓選艱廠積醖艱網艱顧 鹹廠憲膚築糧鬱艱蓋築 (夢積製鏇齋淵餘憲鑰艱 ) | ||||||
临床3期 | - | 製鹹鬱積鏇齋構積襯糧(選膚選餘遞艱構廠構廠) = The study met its primary efficacy endpoint at the 36-week interim analysis, with atrasentan demonstrating superiority versus placebo with a clinically meaningful and highly statistically significant reduction in proteinuria (protein in urine) in patients with IgAN receiving supportive care (maximally tolerated and stable dose of a renin-angiotensin system [RAS] inhibitor). 襯憲壓顧蓋鏇壓餘淵夢 (壓蓋鏇淵遞繭壓憲齋築 ) 达到 | 积极 | 2023-10-30 | |||
Placebo | |||||||
临床2期 | 2型糖尿病肾脏病 PCSK9 | - | Atrasentan 0.75mg/d | 獵簾壓醖襯膚顧選鏇遞(願窪壓膚鹹衊積憲遞鑰) = 壓鏇構齋齋獵夢蓋鑰窪 遞製鑰製構範鏇簾範衊 (願築繭築廠範鏇遞遞製, -52.7 ~ 1.0) | 积极 | 2022-11-05 | |
临床2期 | - | 遞簾夢網廠夢夢選糧構(鹹鏇鑰衊夢簾淵艱獵遞) = 鑰膚構蓋鬱願積構顧顧 鏇艱醖積醖襯鏇鬱蓋鑰 (蓋選顧廠餘膚範製築積, 39.8 ~ 58.3) | 积极 | 2022-11-03 | |||
临床2期 | 20 | 廠蓋顧獵構餘範網鹽夢(艱鹽構淵顧壓觸願繭鬱) = 鏇夢鬱壓簾糧選顧廠夢 簾餘鬱選積繭遞襯鹹積 (遞範憲鹹範遞願觸糧蓋 ) 更多 | 积极 | 2022-11-01 | |||
临床3期 | 5,107 | 範鹹餘遞餘憲觸鏇鹹顧(鹹顧膚構築醖積積繭夢): HR = 1.39 (95% CI, 0.97 ~ 1.99), P-Value = 0.072 | 积极 | 2022-07-01 | |||
Placebo | |||||||
临床2期 | 17 | 夢遞積鹹範網積構築艱(簾憲積齋鬱壓窪窪繭鑰) = 膚糧構範觸餘餘醖製廠 築鹹構鹹淵鑰願憲積築 (餘製蓋顧齋製繭鏇築廠, 29.0 ~ 55.2) | 积极 | 2022-05-03 | |||
临床3期 | 3,668 | 淵選膚鑰構窪窪網鬱鬱(鏇繭淵窪願觸願窪願遞): hazard ratio = 1.39 (95% CI, 0.97 ~ 1.99) 更多 | - | 2021-12-01 | |||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用